Department of Urology, Tianjin First Central Hospital, Nankai University, Tianjin, China.
Department of Pathogen Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, China.
Neoplasma. 2019 May 23;66(3):470-480. doi: 10.4149/neo_2018_181009N753. Epub 2019 Mar 7.
The clinical role of APC promoter methylation in patients with bladder cancer remains to be determined. The relevant databases (PubMed, EMBASE, EBSCO, Wangfang, CNKI and Cochrane Library) were searched to get eligible studies. The overall odds ratios (ORs) and the corresponding 95% confidence intervals (95% CIs) were calculated to assess the effects of APC promoter methylation on bladder cancer risk and clinicopathological features. 2214 patients with bladder cancer and 665 controls were identified. APC promoter methylation was significantly higher in bladder cancer than in nonmalignant tissue and urine samples (tissue: OR = 11.14, 95% CI = 4.29-28.91, P < 0.001; urine: OR = 24.31, 95% CI = 6.26-94.38, P < 0.001), but not in blood samples (P = 0.242). The relationship was observed between APC promoter methylation and gender (male vs. female: OR = 1.46, 95% CI = 0.96-2.22, P = 0.074), tumor stage (stage T2-T4 vs. Ta-T1: OR = 3.00, 95% CI = 1.66-5.42, P < 0.001), and tumor grade (grade 3-4 vs. grade 1-2: OR = 1.99, 95% CI = 1.15-3.42, P = 0.013). But no correlation was found between APC promoter methylation and age, lymph node status, and tumor number (P > 0.1). APC gene was not associated with overall survival of bladder cancer. Our findings indicate that APC promoter methylation may be associated with the development and progression of bladder cancer and may serve as a promising noninvasive biomarker using urine samples for the detection of bladder cancer.
APC 启动子甲基化在膀胱癌患者中的临床作用仍有待确定。检索相关数据库（PubMed、EMBASE、EBSCO、万方、CNKI 和 Cochrane Library）以获取合格的研究。计算总的优势比（OR）和相应的 95%置信区间（95%CI）来评估 APC 启动子甲基化对膀胱癌风险和临床病理特征的影响。共纳入 2214 例膀胱癌患者和 665 例对照。与非恶性组织和尿液样本相比，膀胱癌中 APC 启动子甲基化明显升高（组织：OR=11.14，95%CI=4.29-28.91，P<0.001；尿液：OR=24.31，95%CI=6.26-94.38，P<0.001），但在血液样本中无差异（P=0.242）。APC 启动子甲基化与性别（男性与女性：OR=1.46，95%CI=0.96-2.22，P=0.074）、肿瘤分期（T2-T4 期与 Ta-T1 期：OR=3.00，95%CI=1.66-5.42，P<0.001）和肿瘤分级（3-4 级与 1-2 级：OR=1.99，95%CI=1.15-3.42，P=0.013）有关，但与年龄、淋巴结状态和肿瘤数量无关（P>0.1）。APC 基因与膀胱癌的总生存无关。研究结果表明，APC 启动子甲基化可能与膀胱癌的发生发展有关，尿液样本中 APC 启动子甲基化可能成为膀胱癌非侵入性检测的有前途的生物标志物。
